Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc filed a Form 144 reporting a proposed sale of 4,110 ordinary shares to be executed on 08/11/2025 through Charles Schwab & Co., Inc. The filing lists an aggregate market value of $994,450 and shows 98,490,606 shares outstanding. The shares were acquired on 08/11/2025 via an employee stock option exercise and the payment method is recorded as a broker payment for a cashless exercise.
The notice states no securities were sold by the person in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
STERIS plc filed a Form 144 reporting a proposed sale of 3,495 ordinary shares with an aggregate market value of $844,249, to be sold on the NYSE through Charles Schwab on 08/11/2025. The shares were acquired on 08/11/2025 via an employee stock option exercise and payment was completed through a broker cashless exercise. The filing reports 98,490,606 shares outstanding and states Nothing to Report for securities sold in the past three months. The filing does not identify the person for whose account the securities are to be sold.
STERIS plc reported a Form 144 notice for an insider sale of ordinary shares. The filing shows 7,900 shares offered through Charles Schwab & Co., with an aggregate market value of $1,909,646.00 and 98,490,606 shares outstanding for the company. The shares were acquired and are to be sold on 08/11/2025 via an employee stock option exercise using a broker payment for a cashless exercise.
The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer. Relationship to the issuer and the identity of the selling person are not specified in the visible fields.